Understanding Brokerage Reports On Lupin And Gland Pharma | Halftime Report | CNBC-TV18

Understanding Brokerage Reports On Lupin And Gland Pharma | Halftime Report | CNBC-TV18

Why Brokerages Have Bearish Stance On Pharma Stocks? | Lupin, Zydus Life Brokerage Verdict | ET NowПодробнее

Why Brokerages Have Bearish Stance On Pharma Stocks? | Lupin, Zydus Life Brokerage Verdict | ET Now

Gland Pharma Slips Over 14%, Glenmark, Lupin Receive U.S FDA Observation | Markets Today | CNBC-TV18Подробнее

Gland Pharma Slips Over 14%, Glenmark, Lupin Receive U.S FDA Observation | Markets Today | CNBC-TV18

Lupin's Management Talks About The Company's Q2FY Results | Halftime Report | CNBC-TV18Подробнее

Lupin's Management Talks About The Company's Q2FY Results | Halftime Report | CNBC-TV18

Brokerages Weigh Impact Of US Court's Patent Decision On Zydus Life, Lupin | CNBC TV18Подробнее

Brokerages Weigh Impact Of US Court's Patent Decision On Zydus Life, Lupin | CNBC TV18

Lupin & Zydus Under Spotlight As U.S. Court Issues Restraining Order On Myrbetriq Generic ShipmentsПодробнее

Lupin & Zydus Under Spotlight As U.S. Court Issues Restraining Order On Myrbetriq Generic Shipments

Top 5 Pharma sector company in India | Best stock #shorts #youtubeshortsПодробнее

Top 5 Pharma sector company in India | Best stock #shorts #youtubeshorts

Decoding Gland Pharma's Q2FY23 Results As The Stock Is Down Almost 15% | Halftime Report | CNBC-TV18Подробнее

Decoding Gland Pharma's Q2FY23 Results As The Stock Is Down Almost 15% | Halftime Report | CNBC-TV18

IIFL Note On Pharma Sector: Muted Exports Are Hurting Pharma Companies | Halftime Report | CNBC-TV18Подробнее

IIFL Note On Pharma Sector: Muted Exports Are Hurting Pharma Companies | Halftime Report | CNBC-TV18

Bino Pathiparampil Shares Views On Gland Pharma's Q2FY23 Results | Halftime Report | CNBC-TV18Подробнее

Bino Pathiparampil Shares Views On Gland Pharma's Q2FY23 Results | Halftime Report | CNBC-TV18

Gland Pharma Reports Weak Q1FY25, Revenue Down 16%, Margin Lowest Since Q4FY23 | CNBC TV18Подробнее

Gland Pharma Reports Weak Q1FY25, Revenue Down 16%, Margin Lowest Since Q4FY23 | CNBC TV18

CS On Lupin: Expect A Re-Inspection At Least At Indore Facility & Expect Resolution In H2FY20Подробнее

CS On Lupin: Expect A Re-Inspection At Least At Indore Facility & Expect Resolution In H2FY20

Lupin & I’rom Enter Into Licensing Agreement For Denosumab Biosimilar In Japan | Trading HourПодробнее

Lupin & I’rom Enter Into Licensing Agreement For Denosumab Biosimilar In Japan | Trading Hour

Lupin Slips In Trade As U.S FDA Issues Warning Letter For Tarapur Facility | ChartbustersПодробнее

Lupin Slips In Trade As U.S FDA Issues Warning Letter For Tarapur Facility | Chartbusters

Srinivas Sadu Of Gland Pharma Speaks On Acquiring 100% Of Cenext Group | Trading Hour | CNBC-TV18Подробнее

Srinivas Sadu Of Gland Pharma Speaks On Acquiring 100% Of Cenext Group | Trading Hour | CNBC-TV18

Pharma Sector Outlook: Take A Look At JPMorgan & CITI's View On The Sector | Halftime ReportПодробнее

Pharma Sector Outlook: Take A Look At JPMorgan & CITI's View On The Sector | Halftime Report

IIFL Predicts Mixed Outlook For Indian Pharma In 2023, Bernstein Predicts Improvement In MarginПодробнее

IIFL Predicts Mixed Outlook For Indian Pharma In 2023, Bernstein Predicts Improvement In Margin

Antique Broking Expects Margin Improvement For Lupin, Has A Buy Rating With Target Of Rs 1,220Подробнее

Antique Broking Expects Margin Improvement For Lupin, Has A Buy Rating With Target Of Rs 1,220

What To Expect From The Pharma Sector In Q3FY23? Systematix Group's Vishal Manchanda ExclusiveПодробнее

What To Expect From The Pharma Sector In Q3FY23? Systematix Group's Vishal Manchanda Exclusive

Lupin Management Speaks On The Co's Q4FY23 Earnings & India And US Biz Updates | Halftime ReportПодробнее

Lupin Management Speaks On The Co's Q4FY23 Earnings & India And US Biz Updates | Halftime Report